Vaibhav Agrawal, M.D., M.B.A.

Assistant Professor, Hematology/BMT @cityofhope | Leukemia, Stem cell transplant, Cellular Therapy | B-cell ALL, AML, T-cell ALL |Leukemia survivor

[Vaibhav Agrawal, M.D., M.B.A. @_VaibhavAgrawal]

PAX5-altered adult B-ALL is not one disease.
A 42-patient cohort showed divergent outcomes by alteration; PAX5 fusions independently predicted inferior OS (HR 7.79).
Should PAX5 variant—not simply PAX5 status—inform risk?
https://t.co/CKAqUBuzCH #ALLsm

[Vaibhav Agrawal, M.D., M.B.A. @_VaibhavAgrawal]

Can low-dose ATG improve PTCy?
Among 97 PB allo-HCTs, ATG + attenuated PTCy vs PTCy alone lowered 2-y mod/severe cGVHD: 3.7% vs 17.0% (P=.046), without an observed rise in relapse/NRM.
Worth randomized testing?
https://t.co/6tcqvuDu8A #BMTsm

[Vaibhav Agrawal, M.D., M.B.A. @_VaibhavAgrawal]

Could antibiotics before day 0 weaken GVL?

Among 160 AML/ALL TBI allo-HCTs, early broad-spectrum antibiotics were associated with 2-y relapse: 45% vs 23% (sHR 2.00), without higher NRM.
Microbiome signal—or indication bias? #bmtsm
https://t.co/A65oKZQ37d

[Vaibhav Agrawal, M.D., M.B.A. @_VaibhavAgrawal]

Should CAR-T move before relapse in older B-ALL?

In 18 adults ≥55 in MRD− CR1, CD19 CAR-T yielded 18-mo EFS 84% and OS 100%, with no grade ≥2 CRS or ICANS.

https://t.co/BgkTccgT10 #B-ALL#ALL

Explored further in ongoing clinical trial: NCT07053059

[Blood Journals Portfolio @BloodPortfolio]

New clinical guidelines: American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia. Read in Blood Advances ➡️ https://t.co/jsSN62TTMl

[Haematologica @Haematologica]

Can treosulfan improve outcomes after allogeneic hematopoietic cell transplantation in acute myeloid leukemia?
This study compares treosulfan- versus busulfan-based conditioning
https://t.co/iSW5g7itur

[Vaibhav Agrawal, M.D., M.B.A. @_VaibhavAgrawal]

Can an off-the-shelf bridge make CAR-T practical in T-ALL?

Triple base-edited CAR7 induced morphologic remission in all 11 pts; 9 (82%) reached deep remission and HCT. Seven remain in remission at 3–36 mo—but CD7 loss emerged.

https://t.co/3KeNMoSEEt

[Dr. Minoo Battiwalla @DrBattiwalla]

Allo HCT remains a very effective though underutilized treatment modality for CLL. Cure rate ~70%, which remains higher than CAR-T. Having said that, I haven’t transplanted a CLL in a decade because I simply don’t get the referral.

[Joshua Zeidner MD @LeukDocJZ]

We are entering a new frontier in AML ➡️The Paradigm study now out in @NEJM showing improved EFS in younger non-fav. risk AML Tx with Aza/Ven vs. Intensive chemo. Huge congrats to Amir Fathi & all authors for this incredibly important study & milestone. https://t.co/QiA8cHQKvc

[NEJM @NEJM]

In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. Full PARADIGM trial results: https://t.co/iiDNsw6CUW

Editorial: Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML https://t.co/zsAPQjxEDb

[Talha Badar @TalhaBadarMD]

1/5 For a decade, decitabine has been assumed superior to azacitidine in TP53-mutant AML based on deeper molecular clearance. We tested that assumption in 652 patients across 15 centers #COMMAND_consortium Thread 🧵 #leusm #AML #TP53 https://t.co/dKCje7lhUD @LeukemiaJnl @Dr_AmerZeidan @Anand_88_Patel @Dr_RoryShallis @ShyamPatelMDPhD @yu_hung_wang @vamkota @yasminabaza1 @AlexColtoff @AyaOncologist @CharlieFoucar @MRLitzow @MKD_BMT @hemant_murthy @ChenyuLinMD et al.

[Vaibhav Agrawal, M.D., M.B.A. @_VaibhavAgrawal]

https://t.co/UTa9qEV4ES

[Talha Badar @TalhaBadarMD]

#ASH25 #ASHPlenary
#PARADIGM trial
Great work, congratulations to Dr. Fathi and colleagues! #AML #leusm
Summary:
The study met PE for EFS.
Higher ORR and CR in VEN+AZA gp
More pt received transplant in VEN+AZA gp
Better QOL

[Joshua Zeidner MD @LeukDocJZ]

Huge congratulations to Amir Fathi for delivering one of the most impactful plenary presentations @ASH_hematology in AML in past decade. The PARADIGM study may lead to a Paradigm shift- Aza/Ven > intensive chemo in newly Dx high-risk AML. 👏👏👏

[Haematologica @Haematologica]

New opportunities for an “old” drug! The DEXAML-02 study raises the hypothesis that the addition of dexamethasone to standard intensive induction chemotherapy may improve the outcome of patients with acute myeloid leukemia.
https://t.co/KP3n1pnCFI

[Nico Gagelmann @NicoGagelmann]

Practice-changing study in hematology!

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial

Out in @JCO_ASCO

https://t.co/HKcyOFXaH8

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

In a BMTCTN trial, older patients with higher-risk MDS had better overall survival with HCT compared to non-HCT options. Transplant patients face high out-of-pocket costs, post-transplant, yet costs & financial difficulty generally improve over time: https://t.co/UWztkZaJli

[Hagop Kantarjian,MD @DrHKantarjian]

SQ blinatumomab is highly effective in R-R ALL with CR/CRh rate of 77%, MRD-negativity rate of 91%, and 12-month OS rate of 63-70%.

The 250 µg/500 µg dose was selected as the recommended phase 2 dose.
@MDAndersonNews #Leukemia
https://t.co/7VIh5lDE8y
#leusm

[Talha Badar @TalhaBadarMD]

Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial - The Lancet Haematology https://t.co/2B1MDyDZ7B

1. CR/CRi rate 77% in RR B-cell ALL (compared to 42% with IV Blin), MRD 91% among responders.
2. Debulking required pre-Blin for BM blast > 50%.
3. Interval b/w cycles 1 weeks compared to 2 weeks with IV Blin.
4. GIII neurological adverse events were comparable.
5. Neurological AEs of any grade occurred at a higher frequency in the 500 μg/1000 μg group, the dose level of 250 μg/500 was RP2D #leusm

[AmericanJournalofHematology @AjHematology]

In allo-HSCT recipients, mixed chimerism, especially in #NKcells, predicts relapse. NK-cell MC stratifies relapse risk in MRD-negative patients. Routine NK-chimerism monitoring may improve post-transplant surveillance. #HSCT #MRD #Chimerism
https://t.co/tJ0E7B26ir